Publications by authors named "P A Kosmidis"
Article Synopsis
- Older patients with advanced hormone receptor-positive/HER2-negative breast cancer benefit from combining CDK4/6 inhibitors with standard endocrine therapy, according to recent studies.
- There is a higher risk of side effects from these inhibitors in older patients, leading to a trend of starting them on lower doses, although this practice lacks strong evidence.
- The IMPORTANT-trial aims
Background/aim: Nivolumab is an FDA-approved immune checkpoint inhibitor (ICI) for patients with advanced, pre-treated non-small cell lung cancer (NSCLC). However, treatment profiles and patient outcomes often differ in routine clinical practice while the financial impact of approved therapies is largely unknown. In this study, we investigated the efficacy, tolerability, and economic impact of nivolumab in real-world settings (RWS) in Greece.
View Article and Find Full Text PDFArticle Synopsis
- A European registry was established for patients with advanced EGFR exon 20-mutant non-small cell lung cancer (NSCLC) diagnosed between January 2019 and December 2021, specifically excluding those enrolled in clinical trials.* -
- The final analysis included data from 175 patients across nine countries, revealing a median age of 64 years, predominantly affecting women (56.3%) and mostly comprising adenocarcinoma cases (95.4%) with frequent bone (47.4%) and brain (32.0%) metastases.* -
- Treatment patterns varied significantly: chemotherapy and chemotherapy-immunotherapy combinations were used in 33.8% and 18.2% of cases respectively, with disease control rates of
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.
Br J Cancer
September 2022
Background: Dose-dense sequential chemotherapy with anthracyclines and taxanes achieved an 18% reduction of recurrence risk in early breast cancer (BC). The optimal chemotherapy schedule and interval between cycles remain under investigation.
Methods: Overall, 990 patients were randomised to receive either three cycles of epirubicin (E, 110 mg/m) every 2 weeks followed by 3 cycles of paclitaxel (T, 200 mg/m) every 2 weeks followed by three cycles of intensified CMF (Control Arm A, E-T-CMF) that was previously used in BC or three cycles of epirubicin followed by three cycles of CMF followed by nine consecutive weekly cycles of docetaxel (wD) 35 mg/m (Arm B, E-CMF-wD) or nine consecutive weekly cycles of paclitaxel (wT) 80 mg/m (Arm C, E-CMF-wT).
Introduction: Breast and prostate cancer survivors can experience impaired quality of life (QoL) in several QoL domains. The current strategy to support cancer survivors with impaired QoL is suboptimal, leading to unmet patient needs. ASCAPE aims to provide personalized- and artificial intelligence (AI)-based predictions for QoL issues in breast- and prostate cancer patients as well as to suggest potential interventions to their physicians to offer a more modern and holistic approach on cancer rehabilitation.
View Article and Find Full Text PDF